Ovarian Cancer Treatment Market - Forecasts from 2019 to 2024

June 2019 | 106 pages | ID: OA5CA56F97FCEN
Knowledge Sourcing Intelligence LLP

Abstracts

The ovarian cancer treatment market is projected to grow at a CAGR of 7.02% to reach US$2.505 billion by 2024. The ovarian cancer treatment market is expected to grow at a fast pace during the forecast period due to the growing incidence of ovarian cancer among women worldwide. According to the American Cancer Society, around 22,530 new cases of ovarian cancer will be diagnosed in 2019 and around 13,980 deaths are likely to occur in the same year. Region-wise, North America is expected to hold the highest market share owing to the highest health spending of the United States among all the developed regions. The growing number of clinical trials have improved the chances of new innovations for targeted cancer treatment, emanating the market growth during the forecast period. Growing awareness among women has further led to early diagnosis, further leading to the treatment of ovarian cancer at an early stage, when diagnosed, thus, improving the survival rate of the patients. Currently available treatments include surgery, chemotherapy, radiation therapy, and hormonal therapy.

DRIVERS

Rising ovarian cancer incidence

Growing number of clinical trials for new innovations

Increasing health expenditure

RESTRAINTS

High cost of cancer treatment

INDUSTRY UPDATE

According to the Biospectrum news on 21st June 2019, the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) entered into a collaboration with AstraZeneca for enhancing the quality in cancer for people suffering from advanced ovarian cancer.

Predictive Oncology, previously known as Precision Therapeutics, in April 2019, announced that it has entered into a collaboration with Helomics and Viome to study the link between the gut microbiome and ovarian cancer.

Major industry players profiled as part of the report are Sotio (Member of PPF Group), Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, TESARO, Inc., Clovis Oncology, AbbVie Inc., Oasmia Pharmaceutical AB, ImmunoGen Inc., and Boehringer Ingelheim GmbH.

Segmentation

The ovarian cancer treatment market has been analyzed through the following segments:

By Diagnosis

Blood Tests

Imaging Tests

Laparoscopy

Colonoscopy

Others

By Treatment

Surgery

Radiation Therapy

Chemotherapy

Hormone Therapy

Clinical Trials

By Geography

North America

USA

Canada

Mexico

South America

Brazil

Argentina

Others

Europe

Germany

France

United Kingdom

Spain

Others

Middle East and Africa

Saudi Arabia

Israel

Others

Asia Pacific

China

Japan

South Korea

India

Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

3. KEY FINDINGS

4. MARKET DYNAMICS

4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
  4.5.1. By age group
  4.5.2. By region
4.6. Product Pipeline
4.7. Innovations

5. OVARIAN CANCER TREATMENT MARKET BY DIAGNOSIS

5.1. Blood Tests
5.2. Imaging Tests
5.3. Laparoscopy
5.4. Colonoscopy
5.5. Others

6. OVARIAN CANCER TREATMENT MARKET BY TREATMENT

6.1. Surgery
6.2. Radiation Therapy
6.3. Chemotherapy
6.4. Hormone Therapy
6.5. Clinical Trials

7. OVARIAN CANCER TREATMENT MARKET BY GEOGRAPHY

7.1. North America
  7.1.1. USA
  7.1.2. Canada
  7.1.3. Mexico
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. Germany
  7.3.2. France
  7.3.3. United Kingdom
  7.3.4. Spain
  7.3.5. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. Israel
  7.4.3. Others
7.5. Asia Pacific
  7.5.1. China
  7.5.2. Japan
  7.5.3. South Korea
  7.5.4. India
  7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Sotio (Member of PPF Group)
9.2. Pfizer Inc.
9.3. AstraZeneca
9.4. F. Hoffmann-La Roche Ltd
9.5. TESARO, Inc.
9.6. Clovis Oncology
9.7. AbbVie Inc.
9.8. Oasmia Pharmaceutical AB
9.9. ImmunoGen Inc.
9.10. Boehringer Ingelheim GmbH
LIST OF FIGURES
LIST OF TABLES